Stem definition | Drug id | CAS RN |
---|---|---|
aromatic ring -CH(-OH)-CH2-NH-R | 1531 | 36894-69-6 |
Dose | Unit | Route |
---|---|---|
0.60 | g | O |
0.60 | g | P |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 16 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 2.50 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 104.53 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 25 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 4.80 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 23 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.50 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 4.40 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Aug. 1, 1984 | FDA | CNTY LINE PHARMS |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Exposure during pregnancy | 155.30 | 15.32 | 123 | 5873 | 136219 | 56149852 |
Pre-eclampsia | 120.27 | 15.32 | 42 | 5954 | 8444 | 56277627 |
Caesarean section | 107.21 | 15.32 | 46 | 5950 | 16045 | 56270026 |
Premature delivery | 95.74 | 15.32 | 50 | 5946 | 27010 | 56259061 |
Premature baby | 93.21 | 15.32 | 44 | 5952 | 19161 | 56266910 |
Maternal exposure during pregnancy | 69.68 | 15.32 | 93 | 5903 | 189460 | 56096611 |
Foetal growth restriction | 63.27 | 15.32 | 25 | 5971 | 7074 | 56278997 |
Hypertension | 61.11 | 15.32 | 100 | 5896 | 244178 | 56041893 |
Patent ductus arteriosus | 50.05 | 15.32 | 18 | 5978 | 3933 | 56282138 |
Premature labour | 45.00 | 15.32 | 23 | 5973 | 11859 | 56274212 |
Haemangioma congenital | 43.55 | 15.32 | 10 | 5986 | 436 | 56285635 |
Pregnancy | 42.23 | 15.32 | 32 | 5964 | 33001 | 56253070 |
Foetal exposure during pregnancy | 35.14 | 15.32 | 29 | 5967 | 33794 | 56252277 |
Hypotension | 29.39 | 15.32 | 75 | 5921 | 250433 | 56035638 |
Low birth weight baby | 29.31 | 15.32 | 14 | 5982 | 6244 | 56279827 |
Maternal drugs affecting foetus | 28.85 | 15.32 | 13 | 5983 | 5080 | 56280991 |
Rheumatoid arthritis | 27.58 | 15.32 | 4 | 5992 | 382600 | 55903471 |
HELLP syndrome | 27.19 | 15.32 | 8 | 5988 | 928 | 56285143 |
Foetal death | 25.13 | 15.32 | 14 | 5982 | 8573 | 56277498 |
Post transplant lymphoproliferative disorder | 23.56 | 15.32 | 11 | 5985 | 4661 | 56281410 |
Gestational diabetes | 23.19 | 15.32 | 13 | 5983 | 8051 | 56278020 |
Phaeochromocytoma | 22.41 | 15.32 | 6 | 5990 | 493 | 56285578 |
Exomphalos | 21.80 | 15.32 | 6 | 5990 | 547 | 56285524 |
Ultrasound uterus abnormal | 20.93 | 15.32 | 4 | 5992 | 70 | 56286001 |
Dilatation intrahepatic duct acquired | 20.84 | 15.32 | 6 | 5990 | 644 | 56285427 |
Blood pressure increased | 19.69 | 15.32 | 46 | 5950 | 145130 | 56140941 |
Hyperkalaemia | 18.68 | 15.32 | 25 | 5971 | 50840 | 56235231 |
Drug intolerance | 18.54 | 15.32 | 3 | 5993 | 264815 | 56021256 |
Cardiac arrest | 17.15 | 15.32 | 32 | 5964 | 86282 | 56199789 |
Abortion spontaneous | 16.83 | 15.32 | 22 | 5974 | 43731 | 56242340 |
Red blood cell schistocytes present | 15.71 | 15.32 | 4 | 5992 | 270 | 56285801 |
Kidney transplant rejection | 15.50 | 15.32 | 8 | 5988 | 4205 | 56281866 |
Neuromuscular blockade | 15.34 | 15.32 | 4 | 5992 | 297 | 56285774 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Premature baby | 116.35 | 18.67 | 51 | 3470 | 18015 | 31675808 |
Foetal exposure during pregnancy | 74.78 | 18.67 | 50 | 3471 | 40826 | 31652997 |
Low birth weight baby | 73.35 | 18.67 | 28 | 3493 | 6942 | 31686881 |
Foetal disorder | 72.24 | 18.67 | 17 | 3504 | 793 | 31693030 |
Neutropenia neonatal | 64.45 | 18.67 | 15 | 3506 | 666 | 31693157 |
Foetal growth restriction | 46.22 | 18.67 | 17 | 3504 | 3798 | 31690025 |
Congenital oesophageal anomaly | 44.58 | 18.67 | 8 | 3513 | 93 | 31693730 |
Polyhydramnios | 31.91 | 18.67 | 7 | 3514 | 237 | 31693586 |
Patent ductus arteriosus | 30.63 | 18.67 | 12 | 3509 | 3181 | 31690642 |
Hypertension | 29.82 | 18.67 | 52 | 3469 | 128048 | 31565775 |
Maternal exposure during pregnancy | 29.46 | 18.67 | 13 | 3508 | 4643 | 31689180 |
Anhedonia | 29.33 | 18.67 | 15 | 3506 | 7427 | 31686396 |
Neonatal respiratory distress | 26.40 | 18.67 | 7 | 3514 | 532 | 31693291 |
Newborn persistent pulmonary hypertension | 24.91 | 18.67 | 5 | 3516 | 109 | 31693714 |
Nephrogenic systemic fibrosis | 24.88 | 18.67 | 11 | 3510 | 3944 | 31689879 |
Emotional distress | 24.86 | 18.67 | 17 | 3504 | 14339 | 31679484 |
Injury | 24.29 | 18.67 | 19 | 3502 | 19690 | 31674133 |
Fear | 22.64 | 18.67 | 14 | 3507 | 9960 | 31683863 |
Neonatal cholestasis | 22.41 | 18.67 | 4 | 3517 | 45 | 31693778 |
Ventricular septal defect | 22.40 | 18.67 | 10 | 3511 | 3667 | 31690156 |
Cardiac arrest | 21.80 | 18.67 | 37 | 3484 | 89025 | 31604798 |
Pyelocaliectasis | 21.40 | 18.67 | 7 | 3514 | 1104 | 31692719 |
Renal injury | 19.35 | 18.67 | 13 | 3508 | 10652 | 31683171 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Exposure during pregnancy | 137.82 | 15.17 | 95 | 7231 | 87622 | 70833496 |
Pre-eclampsia | 96.35 | 15.17 | 33 | 7293 | 6452 | 70914666 |
Caesarean section | 87.76 | 15.17 | 36 | 7290 | 11571 | 70909547 |
Hypertension | 77.97 | 15.17 | 122 | 7204 | 295911 | 70625207 |
Premature labour | 47.80 | 15.17 | 21 | 7305 | 7979 | 70913139 |
Maternal exposure during pregnancy | 42.72 | 15.17 | 56 | 7270 | 115289 | 70805829 |
Hypotension | 36.67 | 15.17 | 108 | 7218 | 404273 | 70516845 |
Cardiac arrest | 32.78 | 15.17 | 59 | 7267 | 159775 | 70761343 |
Pregnancy | 30.93 | 15.17 | 23 | 7303 | 23758 | 70897360 |
Kidney transplant rejection | 28.95 | 15.17 | 16 | 7310 | 9945 | 70911173 |
Premature delivery | 26.36 | 15.17 | 20 | 7306 | 21284 | 70899834 |
Phaeochromocytoma | 25.87 | 15.17 | 7 | 7319 | 618 | 70920500 |
Foetal death | 23.75 | 15.17 | 12 | 7314 | 6227 | 70914891 |
Anhedonia | 23.70 | 15.17 | 16 | 7310 | 14197 | 70906921 |
Renal injury | 21.91 | 15.17 | 16 | 7310 | 16078 | 70905040 |
Bradycardia | 21.80 | 15.17 | 43 | 7283 | 124572 | 70796546 |
Foetal growth restriction | 21.79 | 15.17 | 8 | 7318 | 1911 | 70919207 |
Nephrogenic systemic fibrosis | 21.18 | 15.17 | 11 | 7315 | 6041 | 70915077 |
Mental status changes | 20.84 | 15.17 | 29 | 7297 | 63072 | 70858046 |
Myocardial infarction | 20.69 | 15.17 | 51 | 7275 | 171594 | 70749524 |
Dilatation intrahepatic duct acquired | 20.60 | 15.17 | 6 | 7320 | 693 | 70920425 |
HELLP syndrome | 20.47 | 15.17 | 6 | 7320 | 708 | 70920410 |
Fear | 20.32 | 15.17 | 17 | 7309 | 20794 | 70900324 |
Cerebrovascular accident | 19.87 | 15.17 | 45 | 7281 | 143425 | 70777693 |
Renal failure | 19.52 | 15.17 | 53 | 7273 | 189017 | 70732101 |
Abortion spontaneous | 18.67 | 15.17 | 18 | 7308 | 26461 | 70894657 |
Blood pressure increased | 18.62 | 15.17 | 52 | 7274 | 188465 | 70732653 |
Skin induration | 18.54 | 15.17 | 9 | 7317 | 4286 | 70916832 |
Rheumatoid arthritis | 18.11 | 15.17 | 4 | 7322 | 291801 | 70629317 |
Premature baby | 17.28 | 15.17 | 8 | 7318 | 3431 | 70917687 |
Red blood cell schistocytes present | 17.24 | 15.17 | 5 | 7321 | 569 | 70920549 |
Cardiac failure congestive | 17.12 | 15.17 | 41 | 7285 | 135416 | 70785702 |
Emotional distress | 16.86 | 15.17 | 20 | 7306 | 37168 | 70883950 |
Angioedema | 16.82 | 15.17 | 27 | 7299 | 66583 | 70854535 |
Cerebral haemorrhage | 16.67 | 15.17 | 24 | 7302 | 53840 | 70867278 |
Coronary artery disease | 16.63 | 15.17 | 26 | 7300 | 62710 | 70858408 |
Malignant hypertension | 15.94 | 15.17 | 6 | 7320 | 1535 | 70919583 |
Post transplant lymphoproliferative disorder | 15.53 | 15.17 | 11 | 7315 | 10534 | 70910584 |
None
Source | Code | Description |
---|---|---|
ATC | C07AG01 | CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS Alpha and beta blocking agents |
ATC | C07BG01 | CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS AND THIAZIDES Alpha and beta blocking agents and thiazides |
ATC | C07CG01 | CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS AND OTHER DIURETICS Alpha and beta blocking agents and other diuretics |
FDA MoA | N0000000161 | Adrenergic beta-Antagonists |
FDA EPC | N0000175556 | beta-Adrenergic Blocker |
MeSH PA | D018663 | Adrenergic Agents |
MeSH PA | D058668 | Adrenergic alpha-1 Receptor Antagonists |
MeSH PA | D000317 | Adrenergic alpha-Antagonists |
MeSH PA | D018674 | Adrenergic Antagonists |
MeSH PA | D000319 | Adrenergic beta-Antagonists |
MeSH PA | D000959 | Antihypertensive Agents |
MeSH PA | D002317 | Cardiovascular Agents |
MeSH PA | D018377 | Neurotransmitter Agents |
MeSH PA | D018373 | Peripheral Nervous System Agents |
MeSH PA | D013566 | Sympathomimetics |
CHEBI has role | CHEBI:35530 | beta-adrenergic blockers |
CHEBI has role | CHEBI:35674 | antihypertensive drugs |
CHEBI has role | CHEBI:37890 | alpha-adrenergic receptor blockaders |
CHEBI has role | CHEBI:66991 | sympatholytic drug |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Hypertensive disorder | indication | 38341003 | DOID:10763 |
Angina pectoris | off-label use | 194828000 | |
Pheochromocytoma Adjunct Therapy | off-label use | ||
Anuria | contraindication | 2472002 | DOID:2983 |
Bronchospasm | contraindication | 4386001 | |
Hypercholesterolemia | contraindication | 13644009 | |
Secondary angle-closure glaucoma | contraindication | 21571006 | |
Complete atrioventricular block | contraindication | 27885002 | |
Hypovolemia | contraindication | 28560003 | |
Dehydration | contraindication | 34095006 | |
Depressive disorder | contraindication | 35489007 | |
Hyperuricemia | contraindication | 35885006 | DOID:1920 |
Hypokalemia | contraindication | 43339004 | |
Low blood pressure | contraindication | 45007003 | |
Sinus bradycardia | contraindication | 49710005 | |
Systemic lupus erythematosus | contraindication | 55464009 | DOID:9074 |
Sympathectomy | contraindication | 57071006 | |
Hepatic failure | contraindication | 59927004 | |
Hypercalcemia | contraindication | 66931009 | DOID:12678 |
Hyperparathyroidism | contraindication | 66999008 | DOID:13543 |
Hypochloremic alkalosis | contraindication | 70134007 | |
Hepatic coma | contraindication | 72836002 | DOID:12550 |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Pulmonary emphysema | contraindication | 87433001 | |
Cardiogenic shock | contraindication | 89138009 | |
Hyponatremia | contraindication | 89627008 | |
Gout | contraindication | 90560007 | DOID:13189 |
Kidney disease | contraindication | 90708001 | DOID:557 |
Hypomagnesemia | contraindication | 190855004 | |
Partial atrioventricular block | contraindication | 195039008 | |
Decompensated cardiac failure | contraindication | 195111005 | |
Acute pancreatitis | contraindication | 197456007 | DOID:2913 |
Disease of liver | contraindication | 235856003 | DOID:409 |
Neonatal hyperbilirubinemia | contraindication | 281610001 | |
Intraoperative floppy iris syndrome | contraindication | 418801006 | |
Azotemia | contraindication | 445009001 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 8.81 | acidic |
pKa2 | 12.65 | acidic |
pKa3 | 8.23 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Beta-1 adrenergic receptor | GPCR | ANTAGONIST | Ki | 8.23 | DRUG MATRIX | CHEMBL | |||
Beta-2 adrenergic receptor | GPCR | ANTAGONIST | Ki | 7.96 | DRUG MATRIX | CHEMBL | |||
Sigma non-opioid intracellular receptor 1 | Membrane receptor | Ki | 6.12 | DRUG MATRIX | |||||
Sodium-dependent noradrenaline transporter | Transporter | Ki | 5.48 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 1A | GPCR | Ki | 6.65 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 2B | GPCR | Ki | 5.71 | DRUG MATRIX | |||||
Sodium-dependent dopamine transporter | Transporter | Ki | 5.89 | DRUG MATRIX | |||||
Cytochrome P450 2D6 | Enzyme | IC50 | 6.10 | DRUG MATRIX | |||||
Alpha-1D adrenergic receptor | GPCR | ANTAGONIST | Ki | 7.64 | DRUG MATRIX | ||||
Alpha-1B adrenergic receptor | GPCR | Ki | 6.49 | DRUG MATRIX | |||||
Alpha-1A adrenergic receptor | GPCR | IC50 | 7.24 | CHEMBL | |||||
5-hydroxytryptamine receptor 1A | GPCR | IC50 | 6.41 | CHEMBL | |||||
CAAX prenyl protease 1 | Enzyme | AC50 | 5.11 | CHEMBL | |||||
CAAX prenyl protease 2 | Enzyme | AC50 | 4.82 | CHEMBL |
ID | Source |
---|---|
4019797 | VUID |
N0000147886 | NUI |
D00600 | KEGG_DRUG |
32780-64-6 | SECONDARY_CAS_RN |
4018799 | VANDF |
4019797 | VANDF |
C0022860 | UMLSCUI |
CHEBI:6343 | CHEBI |
CHEMBL429 | ChEMBL_ID |
DB00598 | DRUGBANK_ID |
CHEMBL1200323 | ChEMBL_ID |
D007741 | MESH_DESCRIPTOR_UI |
3869 | PUBCHEM_CID |
7207 | IUPHAR_LIGAND_ID |
3941 | INN_ID |
R5H8897N95 | UNII |
202693 | RXNORM |
11828 | MMSL |
201477 | MMSL |
4950 | MMSL |
d00016 | MMSL |
001839 | NDDF |
004368 | NDDF |
372750000 | SNOMEDCT_US |
46547007 | SNOMEDCT_US |
50627005 | SNOMEDCT_US |
CHEMBL1204165 | ChEMBL_ID |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Labetalol Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9320 | INJECTION | 5 mg | INTRAVENOUS | ANDA | 24 sections |
Labetalol HCl in Sodium Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9363 | INJECTION | 1 mg | INTRAVENOUS | NDA | 24 sections |
Labetalol HCl in Sodium Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9363 | INJECTION | 1 mg | INTRAVENOUS | NDA | 24 sections |
Labetalol HCl in Sodium Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9364 | INJECTION | 1 mg | INTRAVENOUS | NDA | 24 sections |
Labetalol HCl in Sodium Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9364 | INJECTION | 1 mg | INTRAVENOUS | NDA | 24 sections |
Labetalol HCl in Sodium Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9365 | INJECTION | 1 mg | INTRAVENOUS | NDA | 24 sections |
Labetalol HCl in Sodium Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9365 | INJECTION | 1 mg | INTRAVENOUS | NDA | 24 sections |
Labetalol HCl in Dextrose | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9366 | INJECTION | 1 mg | INTRAVENOUS | NDA | 24 sections |
Labetalol HCl in Dextrose | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9366 | INJECTION | 1 mg | INTRAVENOUS | NDA | 24 sections |
Labetalol Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9622 | INJECTION | 5 mg | INTRAVENOUS | ANDA | 23 sections |
Labetalol Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9623 | INJECTION | 5 mg | INTRAVENOUS | ANDA | 23 sections |
Labetalol HCl | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0185-0010 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 23 sections |
Labetalol HCl | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0185-0117 | TABLET, FILM COATED | 200 mg | ORAL | ANDA | 23 sections |
Labetalol HCl | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0185-0118 | TABLET, FILM COATED | 300 mg | ORAL | ANDA | 23 sections |
Labetalol Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-2267 | INJECTION, SOLUTION | 5 mg | INTRAVENOUS | ANDA | 12 sections |
Labetalol Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-2339 | INJECTION, SOLUTION | 5 mg | INTRAVENOUS | ANDA | 12 sections |
Labetalol hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-0605 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 22 sections |
Labetalol hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-0606 | TABLET, FILM COATED | 200 mg | ORAL | ANDA | 22 sections |
Labetalol hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-0607 | TABLET, FILM COATED | 300 mg | ORAL | ANDA | 22 sections |
Labetalol HCL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-8130 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 22 sections |
Labetalol HCL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-8131 | TABLET, FILM COATED | 200 mg | ORAL | ANDA | 22 sections |
Labetalol Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6252 | INJECTION | 5 mg | INTRAVENOUS | NDA | 26 sections |
Labetalol hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-5928 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 22 sections |
Labetalol hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-5929 | TABLET, FILM COATED | 200 mg | ORAL | ANDA | 22 sections |
Labetalol hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-5930 | TABLET, FILM COATED | 300 mg | ORAL | ANDA | 22 sections |
Labetalol Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7109 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 19 sections |
Labetalol Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7110 | TABLET, FILM COATED | 200 mg | ORAL | ANDA | 19 sections |
Labetalol Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7111 | TABLET, FILM COATED | 300 mg | ORAL | ANDA | 19 sections |
Labetalol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-641 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 23 sections |
Labetalol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-642 | TABLET, FILM COATED | 200 mg | ORAL | ANDA | 23 sections |